English | 中文版 | 手机版 企业登录 | 个人登录 | 邮件订阅
厂商 仪器 试剂 服务 新闻 文章 视频 高级搜索
当前位置 > 首页 > 行业资讯 > 新闻 > Isoplexis携手典奥助力中国单细胞蛋白组学平台发展
点击次数:3182 发布日期:2018-8-23  来源:本站 本站原创,转载请注明出处

IsoPlexis Announces Expansion into Asia Pacific

Isoplexis与典奥生物在大中华区的合作,闪亮跃上全球新闻发布版面。包括艾伦.戴蒙德艾滋病研究中心的CEO, 同时为Isoplexis科学顾问委员会一员的何大一教授、著名耶鲁大学学者,同时为Isoplexis科学顾问委员会主席的樊荣教授、以及领导精准医学风潮的美国系统生物学研究所总裁Dr. Jim Heath,都为Isoplexis技术在免疫与细胞治疗中所能扮演的重要角色及此次在大中华区的合作感到兴奋与肯定。


IsoPlexis expands sales of its single-cell proteomic analysis platform, IsoLight and IsoCode Chip, to the pharmaceutical and life sciences markets in China

Branford, Conn. (August 20th, 2018)IsoPlexis Corporation (IsoPlexis), a privately held life sciences company at the forefront of single-cell analytics technology, announced today an exclusive agreement with Tekon Biotech, a leading instrumentation distributor, to distribute IsoPlexisproducts in China. Tekon Biotechs first conference featuring IsoPlexiss systems will be held at Purple Mountain Hotel,Pudong, on September 20th in Shanghai.


IsoPlexiss IsoCode & IsoLight system have received numerous awards, recognized as both The Scientist's and Fierce Life Science's #1 innovation of 2017 for the ability to provide both single-cell sensitivity and highly multiplexed and quantitative functional ELISA detection together for the first time.  IsoPlexisIsoLight was also awarded the global Red Dot Design Award in 2018 for its ease of use. These systems will now be available to customers, through its exclusive partner Tekon Biotech, in Mainland China, Hong Kong, Taiwan, and Macau.  


IsoPlexis has published data over the past three years with a variety of leading US CAR-T and Cell Therapy biopharmas and academic institutions, most recently in the journal Blood, where IsoPlexisIsoCode technology predicted whether non-Hodgkin lymphoma patients would respond to CAR-T therapy, directly from the pre-infusion Cell Product. Other pre-infusion metrics from existing technologies tested in this study were not predictive.


We are very excited to partner with Tekon Biotech, a world class distributor of life science systems and technology in China,said IsoPlexis Chief Executive Officer, Sean Mackay. We see significant demand for our unique single-cell platform from leading Chinese pharmaceutical companies, research laboratories, and academic institutions. We are confident this partnership will help accelerate research in the fast emerging CAR-T therapy area in China, as we continue to extend our single-cell leadership into new markets.


"China had emerged as a world leader in CAR-T cell therapies. Fuelled by Chinese biotech investment ($10bn in 2017) and government programs such as 'one three five' development plan and 'Made in China 2025' there are now more CAR-T clinical trials in China than in the US" said Tekon Biotech CEO, David Hadfield. "As we continued to build on Tekon's leadership position in solutions for cell biology into cell therapy and precision medicine, one company repeatedly came up in discussions with leading researchers, Isoplexis. Now we are very pleased to be partnering to bring Isoplexis' unique single-cell solutions to benefit researchers in precision medicine across Greater China.


Dr. David Ho, chief executive officer of the Aaron Diamond AIDS Research Center and IsoPlexis Scientific Advisory Board member, said, Biopharma research and development in China is accelerating at a rapid pace, and IsoPlexis IsoLight system is well positioned to address a critical need in the fast growing field of CAR-T and other cellular immunotherapies.


Dr. Rong Fan, Yale professor and Chair of IsoPlexisScientific Advisory Board, said IsoPlexisIsoCode Chip has demonstrated an improved ability to predict responses of CAR-T patients, from the pre therapy cell product with global leaders in CAR-T.  IsoPlexisIsoLight will benefit our pharma and translational partners internationally by providing  a powerful, yet straightforward solution for establishing immune response functional correlates in the fast moving immunotherapy and cell therapy ecosystem in China.


Dr. Jim Heath, President of leading precision medicine institution, the Institute for Systems Biology, said, The IsoCode Chip will continue to uncover solutions to key challenges not only in CAR-T and cell therapy, but in novel areas of precision medicine as well. IsoPlexissystems will play an important role in profiling immune response in the quickly accelerating Chinese immunology and oncology R&D area.




Tekon Biotech, founded in 1988, sells and supports a broad range of technologies in the China life sciences market. Tekon's customers include all major pharmaceutical and biotech companies plus the top 50 universities. Tekon is headquartered in Shanghai with offices in Hong Kong and Taipei. Tekon Biotech takes pride in providing the best service and technical support. For more information, visit http://www.tekontech.com/.




Data-driven and highly-targeted immunotherapies are the future of the fight against cancer. IsoPlexis, a privately held life sciences company, develops novel end-to-end solutions that are accelerating the revolution in immune and cell-based treatments of cancer. The Isolight, a next-generation analytics platform, profiles responses at the single cell level enabling researchers to generate a precise functional patient signature to help predict and understand complex patient response to cancer immunotherapies. IsoPlexis has partnered with leading biopharmaceutical companies and trial centers to generate real-world data to advance high-need areas of cell product characterization, immune biomarker discovery, and patient monitoring.

For additional information on IsoPlexis, visit http://www.isoplexis.com or email info@isoplexis.com.




Jon Chen

Director of Demand Generation


网友评论 已有[0]人评论
用户名: 密码: 匿名 快速注册 忘记密码
评论只代表网友观点,不代表本站观点。 请输入验证码: 8795
Copyright(C) 1998-2019 生物器材网 电话:021-64166852;13621656896 E-mail:info@bio-equip.com